Epigenomics establishes American Depositary Receipt program
11-Jul-2013
- USA
“In the light of our focused US strategy and the upcoming decision about the approval of our blood-based test for the early detection of colorectal cancer, Epi proColon®, we experience growing interest of US investors,” explained Dr. Thomas Taapken, CEO/CFO of Epigenomics AG. “We established the ADR program as a service to offer those investors an easy way to buy our shares and to consequently broaden the shareholder base in our core market.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.